These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 24917520)

  • 1. Loss of expression of the tumour suppressor gene AIMP3 predicts survival following radiotherapy in muscle-invasive bladder cancer.
    Gurung PM; Veerakumarasivam A; Williamson M; Counsell N; Douglas J; Tan WS; Feber A; Crabb SJ; Short SC; Freeman A; Powles T; Hoskin PJ; West CM; Kelly JD
    Int J Cancer; 2015 Feb; 136(3):709-20. PubMed ID: 24917520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Re: Loss of Expression of the Tumour Suppressor Gene AIMP3 Predicts Survival following Radiotherapy in Muscle-Invasive Bladder Cancer.
    Atala A
    J Urol; 2015 Oct; 194(4):1162-3. PubMed ID: 26382821
    [No Abstract]   [Full Text] [Related]  

  • 3. Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233.
    Mak RH; Hunt D; Shipley WU; Efstathiou JA; Tester WJ; Hagan MP; Kaufman DS; Heney NM; Zietman AL
    J Clin Oncol; 2014 Dec; 32(34):3801-9. PubMed ID: 25366678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MRE11 expression is predictive of cause-specific survival following radical radiotherapy for muscle-invasive bladder cancer.
    Choudhury A; Nelson LD; Teo MT; Chilka S; Bhattarai S; Johnston CF; Elliott F; Lowery J; Taylor CF; Churchman M; Bentley J; Knowles MA; Harnden P; Bristow RG; Bishop DT; Kiltie AE
    Cancer Res; 2010 Sep; 70(18):7017-26. PubMed ID: 20843819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Next-generation sequencing identifies germline MRE11A variants as markers of radiotherapy outcomes in muscle-invasive bladder cancer.
    Teo MTW; Dyrskjøt L; Nsengimana J; Buchwald C; Snowden H; Morgan J; Jensen JB; Knowles MA; Taylor G; Barrett JH; Borre M; Ørntoft TF; Bishop DT; Kiltie AE
    Ann Oncol; 2014 Apr; 25(4):877-883. PubMed ID: 24623370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lymphovascular invasion and the presence of more than three tumors are associated with poor outcomes of muscle-invasive bladder cancer after bladder-conserving therapies.
    Zhang M; Tao R; Zhang C; Shen Z
    Urology; 2010 Oct; 76(4):902-7. PubMed ID: 20709377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Impact of Radiotherapy Facility Volume on the Survival and Guideline Concordance of Patients With Muscle-invasive Bladder Cancer Receiving Bladder-preservation Therapy.
    D'Rummo KA; TenNapel MJ; Shen X
    Am J Clin Oncol; 2019 Sep; 42(9):705-710. PubMed ID: 31368905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abnormal bcl-2 and pRb expression are independent correlates of radiation response in muscle-invasive bladder cancer.
    Pollack A; Wu CS; Czerniak B; Zagars GK; Benedict WF; McDonnell TJ
    Clin Cancer Res; 1997 Oct; 3(10):1823-9. PubMed ID: 9815569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic and Predictive Value of O
    Zhang J; Zhu Y; Wang Y; Fu Q; Xie H; Liu Z; Fu H; Cao Y; Xu J; Dai B
    Ann Surg Oncol; 2018 Jan; 25(1):342-348. PubMed ID: 29116491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of TIP60 (tat-interactive protein) and MRE11 (meiotic recombination 11 homolog) predict treatment-specific outcome of localised invasive bladder cancer.
    Laurberg JR; Brems-Eskildsen AS; Nordentoft I; Fristrup N; Schepeler T; Ulhøi BP; Agerbaek M; Hartmann A; Bertz S; Wittlinger M; Fietkau R; Rödel C; Borre M; Jensen JB; Orntoft T; Dyrskjøt L
    BJU Int; 2012 Dec; 110(11 Pt C):E1228-36. PubMed ID: 23046361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review.
    Ploussard G; Daneshmand S; Efstathiou JA; Herr HW; James ND; Rödel CM; Shariat SF; Shipley WU; Sternberg CN; Thalmann GN; Kassouf W
    Eur Urol; 2014 Jul; 66(1):120-37. PubMed ID: 24613684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The expression profile of p14, p53 and p21 in tumour cells is associated with disease-specific survival and the outcome of postoperative chemotherapy treatment in muscle-invasive bladder cancer.
    Aljabery F; Shabo I; Gimm O; Jahnson S; Olsson H
    Urol Oncol; 2018 Dec; 36(12):530.e7-530.e18. PubMed ID: 30539751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder Cancer.
    Efstathiou JA; Mouw KW; Gibb EA; Liu Y; Wu CL; Drumm MR; da Costa JB; du Plessis M; Wang NQ; Davicioni E; Feng FY; Seiler R; Black PC; Shipley WU; Miyamoto DT
    Eur Urol; 2019 Jul; 76(1):59-68. PubMed ID: 30712971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AIMP3 inhibits cell growth and metastasis of lung adenocarcinoma through activating a miR-96-5p-AIMP3-p53 axis.
    Ding L; Fang Y; Li Y; Hu Q; Ai M; Deng K; Huang X; Xin H
    J Cell Mol Med; 2021 Mar; 25(6):3019-3030. PubMed ID: 33538115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miR-199a-3p and miR-214-3p improve the overall survival prediction of muscle-invasive bladder cancer patients after radical cystectomy.
    Ecke TH; Stier K; Weickmann S; Zhao Z; Buckendahl L; Stephan C; Kilic E; Jung K
    Cancer Med; 2017 Oct; 6(10):2252-2262. PubMed ID: 28879675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment and outcome in muscle invasive bladder cancer: a population-based survey.
    Leliveld AM; Doornweerd BH; Bastiaannet E; Schaapveld M; de Jong IJ
    World J Urol; 2010 Aug; 28(4):439-44. PubMed ID: 20383640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of p53 nuclear overexpression in patients of muscle invasive urinary bladder carcinoma treated with cystectomy.
    Hemal AK; Khaitan A; Dinda AK; Gupta NP; Seth A; Dogra PN; Nabi G
    Urol Int; 2003; 70(1):42-6. PubMed ID: 12566814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histological and immunohistochemical markers for progression prediction in transurethrally resected high-grade non-muscle invasive bladder cancer.
    Kim K; Cho YM; Park BH; Lee JL; Ro JY; Go H; Shim JW
    Int J Clin Exp Pathol; 2015; 8(1):743-50. PubMed ID: 25755769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sensitivity to chemoradiation predicts development of metastasis in muscle-invasive bladder cancer patients.
    Koga F; Numao N; Saito K; Masuda H; Fujii Y; Kawakami S; Kihara K
    Urol Oncol; 2013 Oct; 31(7):1270-5. PubMed ID: 22386622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell cycle inhibitors and outcome after radiotherapy in bladder cancer patients.
    Røtterud R; Pettersen EO; Berner A; Holm R; Olsen DR; Fosså SD
    Acta Oncol; 2002; 41(5):463-70. PubMed ID: 12442923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.